Myelodysplastic Syndrome (Mds): Seeking Cure Through Discovery on Pathogenesis and Disease Progression

The summary for the Myelodysplastic Syndrome (Mds): Seeking Cure Through Discovery on Pathogenesis and Disease Progression grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Myelodysplastic Syndrome (Mds): Seeking Cure Through Discovery on Pathogenesis and Disease Progression: This Request for Applications solicits applications that seek new discoveries in the etiology and pathophysiology of myelodysplastic syndromes (MDS) with the aim to develop new and curative treatment options in the future. A separate RFA HL-04-034 (please see http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-04-034.html) is directed towards myeloproliferative disorders. Applicants are directed to apply to one or the other but not both RFAs.

Federal Grant Title:	Myelodysplastic Syndrome (Mds): Seeking Cure Through Discovery on Pathogenesis and Disease Progression
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-04-033
Type of Funding:	Grant
CFDA Numbers:	93.839
CFDA Descriptions:	Blood Diseases and Resources Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Feb 16, 2005
Posted Date:	May 24, 2004
Creation Date:	May 24, 2004
Archive Date:	Mar 18, 2005
Total Program Funding:
Maximum Federal Grant Award:	$350,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: County governments State governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immu...; • New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional); • Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...; • Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional); • Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional); • Improved Therapy for Hemophilia and Hereditary Bleeding Disorders; • Clinical Hematology Research Career Development Program (K12); • Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...